Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06133816 · ClinicalTrials.gov registry record · NA
Lung Cancer Screening Eligibility Assessment
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 6,125
- Enrollment target
NCT06133816: Completed NA study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT06133816 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 6,125 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (337% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06133816, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 6,125 participants
- Enrollment target
Study Summary
The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.
Primary Outcome
The proportion of participants that answers all three survey questions via text message among all those randomized.
Interventions
- BEHAVIORAL Framed Introductory Message A
- BEHAVIORAL Framed Introductory Message B
- BEHAVIORAL Framed Introductory Message C
- BEHAVIORAL Framed Tobacco Use Message A
- BEHAVIORAL Framed Tobacco Use Message B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,125 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2024-01-31 |
| Phase | NA |
What the finished NCT06133816 record still lists
NCT06133816 is an interventional study that assigns participants to a tested intervention. Its 6,125 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (337% higher).
The record links to 0 conditions, and to 5 interventions - of which Framed Introductory Message A is the first listed.
NCT06133816 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06133816 about?
NCT06133816 is a clinical study titled "Lung Cancer Screening Eligibility Assessment". The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the ...
What is the current status of trial NCT06133816?
This trial is currently completed. It is a NA study. The enrollment target is 6,125 participants. The study started on 2023-07-31. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT06133816?
The interventions under investigation include: Framed Introductory Message A (BEHAVIORAL), Framed Introductory Message B (BEHAVIORAL), Framed Introductory Message C (BEHAVIORAL), Framed Tobacco Use Message A (BEHAVIORAL), Framed Tobacco Use Message B (BEHAVIORAL).
Who is sponsoring clinical trial NCT06133816?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06133816's enrollment target sits among peer trials
6,125 22nd of 2000 higher than 1,979 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04774159 · 6,150 participants · Phase 3
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
- NCT06304168 · 6,150 participants
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
- NCT07166861 · 6,080 participants · NA
Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2
- NCT07049861 · 6,200 participants · NA
Advancing Biopsychosocial Care Training Initiative
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI